Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04258683
Title A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Myeloma Research Group
Age Groups: adult | senior
Covered Countries CAN

No variant requirements are available.